Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of rotigotine in early-stage Parkinson's disease
NCT00594165Phase 3Completed
- Sponsor
- UCB
- Start
- Jun 2002
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of rotigotine in Parkinson's disease (PD), sponsored by UCB. Primary endpoint: Number of Subjects With at Least One Adverse Event at 7 years. Started Jun 2002; status: completed.
02
Drugs
rotigotine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00594165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00594165.